Back to top
more

Eton Pharmaceuticals (ETON)

(Real Time Quote from BATS)

$14.38 USD

14.38
139,244

+0.25 (1.77%)

Updated Aug 4, 2025 02:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Eton Pharmaceuticals (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why

by Zacks Equity Research

Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

by Zacks Equity Research

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -22.22% and 6.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -19.05% and 6.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline

by Zacks Equity Research

Merus (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research

Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of 0% and 9.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.

Zacks Equity Research

Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?

by Zacks Equity Research

Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Here's Why Momentum in Eton Pharmaceuticals (ETON) Should Keep going

by Zacks Equity Research

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

New Strong Buy Stocks for January 28th

by Zacks Equity Research

PBPB, BBCP, BAK, NVAX and ETON have been added to the Zacks Rank #1 (Strong Buy) List on January 28, 2024.

Zacks Equity Research

Here's What Could Help Eton Pharmaceuticals (ETON) Maintain Its Recent Price Strength

by Zacks Equity Research

Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Strength Seen in Eton Pharmaceuticals (ETON): Can Its 10.8% Jump Turn into More Strength?

by Zacks Equity Research

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -7.09% and 54.87%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -125% and 5.03%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 19.23% and 108%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -2.27% and 61.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

Zacks Equity Research

Moderna (MRNA) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 170.51% and 10.32%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

5 Under-$15 Stocks Wall Street Analysts Recommend Buying

by Sanghamitra Saha

After a stellar rally in Wall Street this year, investors with limited funds but desire to participate in the market can bet on low-priced top-ranked stocks like Eton Pharmaceuticals (ETON), LegalZoom.com (LZ), PLAYSTUDIOS (MYPS), American Public Education (APEI) and Cellebrite DI (CLBT).

Zacks Equity Research

Gilead Sciences (GILD) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 19.90% and 4.08%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharma (ETON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the third quarter of 2023 are expected to have been driven by the sales of its marketed products.

Zacks Equity Research

Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery

by Zacks Equity Research

Bayer (BAYRY) collaborates with Twist Bioscience to advance breakthrough innovations based on new scientific approaches and platform technologies.